Search results for "Melanoma-Specific Antigens"

showing 9 items of 9 documents

Residual tumor micro-foci and overwhelming regulatory T lymphocyte infiltration are the causes of bladder cancer recurrence

2016

Bladder cancer has an unexplained, high recurrence rate. Causes of recurrence might include the presence of sporadic tumor micro-foci in the residual urothelial tissue after surgery associated with an inverted ratio between intratumoral effector and regulatory T cell subsets. Hence, surgical specimens of both tumors and autologous, macroscopically/histologically free-of-tumor tissues were collected from 28 and 20 patients affected by bladder or renal cancer, respectively. The frequencies of effector (IFNγ+ and IL17+ T cells) and regulatory (CD4+CD25hiCD127lo and CD8+CD28-CD127loCD39+ Treg) T cell subpopulations among tumor infiltrating lymphocytes were analyzed by immunofluorescence, while …

0301 basic medicinePathologyNeoplasm ResidualT-LymphocytesMessengerImmunoenzyme TechniqueFluorescent Antibody TechniqueCD8-Positive T-LymphocytesT-Lymphocytes RegulatoryImmunoenzyme TechniquesTh10302 clinical medicineLymphocytesReverse Transcriptase Polymerase Chain ReactionResearch Paper: ImmunologyPrognosisRegulatoryBladder cancer; Immune response; Immunity; Immunology and microbiology section; Mage; Th1; Th17; Tumor infiltrating lymphocytes; CD8-Positive T-Lymphocytes; Case-Control Studies; Fluorescent Antibody Technique; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphocytes Tumor-Infiltrating; Melanoma-Specific Antigens; Neoplasm Grading; Neoplasm Proteins; Neoplasm Recurrence Local; Neoplasm Staging; Neoplasm Residual; Prognosis; RNA Messenger; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; T-Lymphocytes Regulatory; Urinary Bladder Neoplasms; OncologyNeoplasm Proteinsmedicine.anatomical_structureLocalOncologytumor infiltrating lymphocytesResidual030220 oncology & carcinogenesisImmunology and Microbiology Sectionbladder cancerTh17Case-Control StudieMelanoma-Specific AntigenMelanoma-Specific AntigensHumanmedicine.medical_specialtyPrognosiRegulatory T cellT cellReal-Time Polymerase Chain ReactionMAGEFollow-Up StudieNeoplasm Protein03 medical and health sciencesLymphocytes Tumor-InfiltratingImmune systemAntigenmedicineHumansTumor-InfiltratingRNA MessengerImmune responseNeoplasm StagingBladder cancerTumor-infiltrating lymphocytesbusiness.industryImmunityCD8-Positive T-LymphocyteT lymphocytemedicine.diseaseNeoplasm Recurrence030104 developmental biologyUrinary Bladder NeoplasmsCase-Control StudiesNeoplasmRNANeoplasm GradingNeoplasm Recurrence Localtumor infiltrating lymphocytebusinessCD8Follow-Up StudiesOncotarget
researchProduct

Primary oral melanoma : a histopathological and immunohistochemical study of 22 cases of Latin America

2011

Objective: The aim of this study was to analyze the histopathological and immunohistochemical characteristics of 22 cases of primary oral melanomas (OM). Study Design: Twenty two cases of primary oral melanoma were analyzed by description of their histopathological features and immunohistochemical study using the antibodies S-100, HMB-45, Melan-A and Ki-67. Results: The mean age was 58 years and 14 cases were female. The main affected sites were the hard palate, followed by the upper gingiva. Microscopically, 15 cases presented level III of invasion, 2 cases were amelanotic and 13 showed a mixed epithelioid and plasmacytoid or spindle cells composition. Some cases showed necrosis, perivascu…

AdultMalePathologymedicine.medical_specialtyNecrosisProliferative indexPerineural invasionYoung AdultMART-1 AntigenmedicineHumansGeneral DentistryMelanomaAgedMouth neoplasmAged 80 and overOral Medicine and Pathologybusiness.industryMelanomaS100 ProteinsMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]Immunohistochemistrymedicine.anatomical_structureKi-67 AntigenLatin AmericaOtorhinolaryngologyUNESCO::CIENCIAS MÉDICASImmunohistochemistrySurgeryHistopathologyResearch-ArticleFemaleMouth NeoplasmsHard palatemedicine.symptombusinessMelanoma-Specific Antigensgp100 Melanoma Antigen
researchProduct

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptidesin vivo: Implications for tumor vaccines with melanoma-associated…

1996

Peptide epitopes derived from differentiation antigens of the melanocyte lineage have been identified in human melanomas and normal cultured melanocytes as targets for MHC-restricted cytotoxic T lymphocytes (CTL). Characterization of multiple CTL-defined antigenic determinants and the presence of corresponding precursor CTL open perspectives for the development of antigen-based vaccines. In the present study, we determined the CTL reactivity against melanoma-associated peptides derived from Melan A/MART-1, tyrosinase and gp100/Pmel17 in 10 HLA-A2+ melanoma patients and 10 healthy individuals. Then, we examined the immunological effects and toxicity of intradermal inoculation of synthetic me…

AdultMaleSignal peptideCancer ResearchInjections IntradermalMolecular Sequence DataTyrosinase Peptide10050 Institute of Pharmacology and Toxicology610 Medicine & healthchemical and pharmacologic phenomenaPeptideEpitopeImmune systemAntigenAntigens NeoplasmHumansCytotoxic T cellMedicine1306 Cancer ResearchHypersensitivity DelayedAmino Acid SequenceMelanomaCells CulturedAgedchemistry.chemical_classificationVaccinesbusiness.industryMiddle AgedNeoplasm ProteinsCTL*OncologychemistryImmunology570 Life sciences; biology2730 OncologyFemalebusinessMelanoma-Specific AntigensT-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injec…

2001

Dendritic cells (DCs) elicit potent anti-tumoral T-cell responses in vitro and in vivo. However, different types of DC have yet to be compared for their capacity to induce anti-tumor responses in vivo at different developmental stages. Herein, we correlated the efficiencies of different types of monocyte-derived DC as vaccines on the resulting anti-tumor immune responses in vivo. Immature and mature DCs were separately pulsed with a peptide derived from tyrosinase, MelanA/MART-1 or MAGE-1 and a recall antigen. Both DC populations were injected every 2 weeks in different lymph nodes of the same patient. Immune responses were monitored before, during and after vaccination. Mature DCs induced …

CD4-Positive T-LymphocytesCancer Researchmedicine.medical_treatmentT cellchemical and pharmacologic phenomenaCD8-Positive T-LymphocytesInterferon-gammaImmune systemAdjuvants ImmunologicAntigenAntigens NeoplasmHumansMedicineCytotoxic T cellAntigen-presenting cellMelanomaNeoplasm Stagingbusiness.industryDendritic CellsImmunotherapyDendritic cellNeoplasm Proteinsmedicine.anatomical_structureOncologyImmunologyImmunizationLymph NodesPeptidesbusinessMelanoma-Specific AntigensCD8T-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

Clonal expansion of melan a-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated pept…

2000

Peptides derived from human tumor antigens have been used in a number of clinical trials to induce specific immune responses against autologous tumors in cancer patients. Although favorable clinical results were observed in single patients, immune responses correlating with tumor regression were either not detected or in case of responses, the T-cell specificity was difficult to demonstrate. In this study, we analyzed antigen-specific T-cell responses induced in the skin and in peripheral blood lymphocytes (PBL) in an HLA-A2-positive melanoma patient. The patient showed major regression of metastatic melanoma under continued immunization with peptides derived from the melanocyte differentia…

Cancer ResearchCellular immunitymedicine.medical_treatmentVitiligochemical and pharmacologic phenomenaMART-1 AntigenMelanocyte differentiationAntigenAntigens NeoplasmmedicineHumansCytotoxic T cellHypersensitivity DelayedMelanomaneoplasmsintegumentary systembusiness.industryMelanomaT-cell receptorImmunotherapyMiddle Agedmedicine.diseaseNeoplasm ProteinsCTL*OncologyImmunologyFemaleImmunizationbusinessMelanoma-Specific AntigensT-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma.

1991

Many human melanoma tumors express antigens that are recognized in vitro by cytolytic T lymphocytes (CTLs) derived from the tumor-bearing patient. A gene was identified that directed the expression of antigen MZ2-E on a human melanoma cell line. This gene shows no similarity to known sequences and belongs to a family of at least three genes. It is expressed by the original melanoma cells, other melanoma cell lines, and by some tumor cells of other histological types. No expression was observed in a panel of normal tissues. Antigen MZ2-E appears to be presented by HLA-A1; anti-MZ2-E CTLs of the original patient recognized two melanoma cell lines of other HLA-A1 patients that expressed the ge…

MAGEA3Melanoma-associated antigenMultidisciplinaryAntigenImmunologyCancer researchCancer/testis antigensSART3Human leukocyte antigenNY-ESO-1Melanoma-Specific AntigensBiologyJournal of immunology (Baltimore, Md. : 1950)
researchProduct

Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo.

1996

Peptide epitopes derived from differentiation antigens of the melanocyte lineage were recently identified in human melanomas as targets for MHC-restricted cytotoxic T lymphocytes (CTL). The characterization of multiple CTL-defined antigenic determinants has opened possibilities of development of antigen-targeted vaccines. In the present study, we determined CTL reactivity against melanoma-associated peptides derived from Melan A/MART-1, tyrosinase, and gp100/Pmel17 in 3 HLA-A2+ melanoma patients. Then, we assessed the immune responses to synthetic melanoma-associated peptides injected intradermally. After 3 cycles of immunization with peptide alone, we used systemic GM-CSF as an adjuvant du…

MaleCancer ResearchCellular immunitymedicine.medical_treatmentMolecular Sequence Data10050 Institute of Pharmacology and Toxicology610 Medicine & healthchemical and pharmacologic phenomenaActive immunizationEpitopeImmune systemAntigenAdjuvants ImmunologicAntigens NeoplasmmedicineCytotoxic T cellHumans1306 Cancer ResearchHypersensitivity DelayedAmino Acid SequenceMelanomabusiness.industryGranulocyte-Macrophage Colony-Stimulating FactorImmunotherapyMiddle AgedImmunohistochemistryNeoplasm ProteinsCTL*OncologyImmunology570 Life sciences; biology2730 OncologyFemaleImmunizationbusinessMelanoma-Specific AntigensT-Lymphocytes CytotoxicInternational journal of cancer
researchProduct

Erythrophagocytic tumour cells in melanoma and squamous cell carcinoma of the skin

1997

Aims: Erythrophagocytosis is a characteristic feature of tumour cells in malignant histiocytosis, some leukaemias, lymphomas, and also reactive histiocytes in the haemophagocytic syndrome associated with a variety of infections and neoplasms. It has also been found exceptionally in metastatic malignant epithelial cells in bone marrow and lymph nodes. We present two cases, a cutaneous malignant melanoma and an acantholytic squamous cell carcinoma, in which erythrophagocytosis by tumour cells was demonstrable by both light and electron microscopy. Methods and results: The melanocytic and squamous nature of these cells was supported by the immunohistochemical detection of HMB45, S100, and NKI-…

MalePathologymedicine.medical_specialtyErythrocytesSkin NeoplasmsHistologyMalignant histiocytosisBiologyPathology and Forensic MedicineCytokeratinPhagocytosisAntigens NeoplasmBiomarkers TumormedicineHumansMelanomaHistiocyteAgedAged 80 and overMelanomaMucin-1General Medicinemedicine.diseaseImmunohistochemistryErythrophagocytosisNeoplasm ProteinsMicroscopy ElectronHaematopoiesismedicine.anatomical_structureEpidermoid carcinomaCarcinoma Squamous CellBone marrowMelanoma-Specific AntigensHistopathology
researchProduct

Primary malignant melanoma of the oral cavity: case report.

2002

An 80-year-old-female patient had a pigmented lesion on: the hard palate, the soft palate, the alveolar mucosa and the vestibolar mucosa of the maxillary gingiva. Pigmented macules and patchs had been persistent and asymptomatic for many years (Fig. 1). The lesion exhibited irregularities of pigmentation, border and surface contour. About 1 year later the patient had noticed an extension of the pigmented macules and plaques; there was also the appearance of nodules of the maxillary gingiva accompanied by swelling. Loosening of teeth as a result of extensive destruction of bone was further noted (Fig. 2). Figure 1. Pigmented macules and patchs with irregularities of pigmentation, border and …

Pathologymedicine.medical_specialtyDermatologyS100 proteinLesionDiagnosis DifferentialDermisAntigens NeoplasmSubmucosamedicineHumansMelanomaAlveolar mucosaAgedAged 80 and overbusiness.industryS100 ProteinsAnatomyImmunohistochemistryNeoplasm Proteinsmedicine.anatomical_structureFemaleMouth NeoplasmsHard palateEpidermismedicine.symptombusinessEpithelioid cellMelanoma-Specific AntigensInternational journal of dermatology
researchProduct